Close Menu

NEW YORK – San Francisco-based Calithera Biosciences on Thursday said that it had dosed the first patient in a Phase II clinical trial of its investigational agent telaglenastat plus chemotherapy and the immune checkpoint inhibitor pembrolizumab (Merck's Keytruda) in first-line advanced, KEAP1- or NRF2-mutated non-small cell lung cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Nov
03

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context.